Immunomonitoring of MSC-Treated GvHD Patients Reveals Only Moderate Potential for Response Predictio...
Immunomonitoring of MSC-Treated GvHD Patients Reveals Only Moderate Potential for Response Prediction but Indicates Treatment Safety
About this item
Full title
Author / Creator
Publisher
United States: Elsevier Limited
Journal title
Language
English
Formats
Publication information
Publisher
United States: Elsevier Limited
Subjects
More information
Scope and Contents
Contents
Mesenchymal stromal cells (MSCs) are used as salvage therapy to treat steroid-refractory acute graft-versus-host disease (aGvHD). We studied the immunological response to MSC treatment in 16 aGvHD patients by assessing lymphocyte profiles and three proposed aGvHD serum markers during the MSC treatment. Surprisingly, there were no obvious difference...
Alternative Titles
Full title
Immunomonitoring of MSC-Treated GvHD Patients Reveals Only Moderate Potential for Response Prediction but Indicates Treatment Safety
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_10f41fb7114346d583caa5327b369bf7
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_10f41fb7114346d583caa5327b369bf7
Other Identifiers
ISSN
2329-0501
E-ISSN
2329-0501
DOI
10.1016/j.omtm.2018.02.001
